MaxCyte IPO Presentation Deck

-40% of Clinical Programs Utilizing Non-Viral Delivery Already Captured; More Discussions Ongoing Diversified Supplier Therapeutic Developers Source: Company Estimates *Percentages are approximate and sum to greater than 100% July 2021 Non-Viral Delivery Competitor Share - Clinical Programs, U.S. Only 10% 20% n=~40 Non-Viral Delivery Clinical Programs (Estimated*) 20% 40% MaxCyte MaxCyte (in discussions) Therapeutic Developers 15% Pure-play Cell Engineering M MaxCyte Delivery Technology Undisclosed Diversified Supplier CONFIDENTIAL Non-viral delivery adoption is driven by: Nuclease mediated gene editing Complex engineering, next-generation approaches High cost and complexities of viral vector manufacturing M MaxCyte 26

View entire presentation